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Objective: In our study, we aimed to evaluate the inﬂuence of training on compliance and persistence
with bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosis
patients.
Methods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2 ± 7.2 years) were
included in this national, multicenter, prospective non-interventional observational cohort registry
study. Patients were randomized into training (n ¼ 492, 50.3%, mean age: 63.4 ± 7.2 years) and control
(n ¼ 487, 49.7%, mean age: 63.0 ± 7.1 years) groups. Patients in each intervention group were given
weekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%,
respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-month
intervals throughout 12 months of treatment for evaluation of persistence, compliance and adverse
events.
Results: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 days
of duration during the 12-month follow-up period. The mean compliance in the compliant and fully
compliant group remained at an average of 86.6%. No signiﬁcant difference was detected between the
training and control groups in terms of compliance and persistence. Signiﬁcantly longer persistence
(360.0 ± 89.0 vs. 345.0 ± 108.0 days; p ¼ 0.035), higher percentage of persistent patients (83.4% vs. 74.2%;
p ¼ 0.012) and higher compliance rates (88.8% vs. 83.3%; p ¼ 0.002) were noted in monthly regimen
patients in comparison to those given weekly regimen.pas¸a School of Medicine, Department of Physical Therapy and Rehabilitation, _Istanbul, Turkey.
ırmak).
iation of Orthopaedics and Traumatology.
umber of patients enrolled by the centers) are listed in the Appendix.
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Ü. Akarırmak et al. / Acta Orthopaedica et Traumatologica Turcica 50 (2016) 415e423416Conclusion: Our ﬁndings revealed remarkably high rates for persistence and compliance with
bisphosphonate treatment in postmenopausal osteoporosis, with no impact of training on compliance
and persistence rates. Longer persistence and better compliance rates were achieved with the monthly
bisphosphonate regimen when compared to the weekly regimen.
© 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Due to their efﬁcacy in preserving bone mass and preventing
fractures,1 bisphosphonates are commonly prescribed treatments
for osteoporosis.2 As with other chronic conditions that are initially
asymptomatic,3 failure of osteoporotic patients to follow the
treatment prescribed (compliance) for the recommended duration
(persistence) has been consistently reported.4e6
Improved adherence to antiresorptive therapy is more likely to
signiﬁcantly reduce osteoporosis-related fracture risk, use of phy-
sicians' services, and hospitalization rates.7 Therefore, several in-
terventions for increasing patients persistence and compliance
with bisphosphonate treatments have been developed in recent
years, including reducing dosing frequency via new therapeutic
options with longer dosing regimens, educational programs, and
patient counseling by nurses.1,4
The present national multicenter prospective non-interventional
observational cohort registry study was designed to evaluate the
inﬂuence of patient training on compliance and persistence with
bisphosphonate treatment prescribed on a weekly vs monthly basis
in patients with postmenopausal osteoporosis in Turkey.
Patients and methods
A total of 979 patients with postmenopausal osteoporosis (mean
[SD] age: 63.2 [7.2] years) were included in this national multi-
center prospective non-interventional observational cohort regis-
try study conducted from February 2010 to September 2012 at 34
centers across Turkey. These clinics were selected on the basis of
presence of an osteoporosis outpatient clinic and applicable local
Standard Operating Procedure for selecting potential investigators
and study sites. This study was conducted in 16 cities and 6
geographic regions throughout Turkey and included 22 community
based hospitals, 12 university hospitals, and 3 private practice
clinics. Of 1010 patients initially screened from 37 centers, 979
patients from 34 centers who met eligibility criteria were enrolled
in the study and included in the ﬁnal analysis. After enrollment,
patients were randomized through an Interactive Voice Response
system into training (n ¼ 492, 50.3%, mean [SD] age: 63.4 [7.2]
years) and control (n ¼ 487, 49.7%, mean [SD] age: 63.0 [7.1] years)
groups. Following medical evaluation and at the discretion of the
physicians, patients in the training and control groups were pre-
scribed weekly (44.9% and 44.6%, respectively) or monthly (55.1%
and 55.4%, respectively) bisphosphonate regimens. Patients were
followed up after the initial visit (visit 1, day 0) and then at 3-month
intervals over the 12-month course of treatment.
Female patients aged 45 and  75 years who were clinically
diagnosed by the investigator with postmenopausal osteoporosis
according to WHO criteria and were appropriate for bisphospho-
nate therapy as deﬁned clinically by the investigator were included
in the present study. Patients enrolled in this registry study either
were currently being treated for osteoporosis with bisphospho-
nates or were treatment-naïve at baseline. Patients receiving other
osteoporosis treatments such as selective estrogen receptor mod-
ulators, hormone replacement therapy, calcitonin, or strontiumranelate, and patients with secondary osteoporosis were excluded
from the study.
Written informed consent was obtained from each subject
following a detailed explanation of the objectives and protocol of
the study, which was conducted in accordance with the ethical
principles stated in the Declaration of Helsinki and approved by the
Turkish Ministry of Health according to local regulations.
Data on socio-demographic and clinical- and osteoporosis-
related history (fractures, bone density measurements, dorsal
kyphosis, and previous anti-osteoporosis treatments) were recor-
ded for each patient at baseline. Data on persistence and compli-
ance with treatment as well as study withdrawal were recorded
during follow-up visits at months 3, 6, 9, and 12. Adverse event (AE)
information was collected upon spontaneous reporting of the
physicians. The primary endpoint of the study was the persistence
and compliance with treatment based on the information given to
the investigator by the patient. The secondary endpoint of the study
was the effect of bisphosphonate treatment on withdrawals from
the study due to AEs.
At the baseline visit, patients randomized to the training group
were supplied with a “Training Kit,” including 4 training booklets
(General Information on Osteoporosis, Osteoporosis and Exercise,
Osteoporosis and Nutrition, Osteoporosis and Patient Rights) con-
taining information on the disease, prepared by the Osteoporosis
Patient Society of Turkey. During 12-month follow-up, 4 telephone
calls (at months 2, 5, 8, and 11 of treatment) and 4 individual face-
to-face interactive/educational meetings (at months 3, 6, 9, and 12
of treatment, covering awareness about osteoporosis, risk factors of
osteoporosis, fractures, prevention, and treatment of osteoporosis)
were conducted. During the telephone calls, patients were
reminded to read the booklets, informed of the topic to be covered
in the next educational meeting, and invited to themeeting. Patient
education in the control group was implemented by physicians, as
per routine clinical practice, without supplying training booklets.
Persistence was deﬁned as the time from initiation to discon-
tinuation of bisphosphonate treatment and measured as the
number of days from the date of the index prescription to the
theoretical end of the last prescription issued during the follow-up
period. Women were considered to have discontinued treatment if
the gap between the end of one prescription and the start of
another was >30 days. The proportion of women who persisted
with treatment for 12 months was also determined.
Rate of compliance was deﬁned as the proportion of days within
the follow-up period for which patients were given a prescription
for bisphosphonate. Patients were classiﬁed by their treating doc-
tors at each visit as non-compliant (0e50% drug intake), partially
compliant (50% drug intake), compliant (75% drug intake) and fully
compliant (100% drug intake).
Assuming adherence to be improved via patient training and a
treatment persistence rate of 70% in the trained patient group and
60% in the control group, with a power of [1 e beta] 90% and a 2-
way error (alpha) estimated at 5%, sample size calculation
revealed at least 476 patients were required for each group.
Considering possible patient loss to follow-up, 500 patients were
sought for each arm.
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Corp LP, College Station, TX, USA). Chi-square (c2) test was used for
the comparison of categorical data, and ManneWhitney U test and
Student's t-test were used for numerical data. Additionally,
KaplaneMeier curves were plotted for treatment persistence, and
the effects of training on treatment compliance and persistence
were evaluated by multivariate analysis. Due to the fact that this
was a non-interventional disease registry study, patients lost to
follow-up for any reasonwere considered as discontinued from the
study. Missing data for these patients on the corresponding visits
were not analyzed. Data were expressed as mean (SD), mini-
mumemaximum, and percent (%) where appropriate. Statistical
signiﬁcance was considered as p < 0.05.
Results
In the training group, 164 of 221 patients (74.2%) on a weekly
regimen and 226 of 271 patients (83.4%) on a monthly regimen
completed the study. In the control group, 166 of 217 patients
(76.5%) on a weekly regimen and 221 of 270 patients (81.0%) on a
monthly regimen completed the study (Fig. 1).
Baseline general and osteoporosis-related characteristics are
presented in Table 1 and Table 2, respectively.
For their bisphosphonate regimen, 56.2% of patients received
70 mg alendronate, and 43.8% received 35 mg risedronate on a
weekly basis; 38.8% of patients received 150 mg ibandronate, 40.1%
received 75 mg risedronate, and 21.1% received 150 mg risedronate
on a monthly basis (Table 2).
The percentage of persistent patients was 79.3% for the training
group and 79.5% for the control group. Overall duration of treat-
ment persistencewas 353 (97.8) days, with no signiﬁcant difference
between training and control groups (Table 3), as also shown via
KaplaneMeier analysis (p ¼ 0.971, Log-rank ManteleCox evalua-
tion) (Fig. 2a).
Duration of treatment persistence was signiﬁcantly longer in
patients on a monthly rather thanweekly bisphosphonate regimen
in the overall study population (360.0 [89.0] vs 345.0 [108.0] days,
respectively; p ¼ 0.035) (Table 3), as also conﬁrmed by
KaplaneMeier analysis (18.7 [0.4] vs 16.8 [1.0] months, respec-
tively; p ¼ 0.007, Log-rank ManteleCox) (Fig. 2b).
Persistence rate was signiﬁcantly higher in patients on a
monthly rather thanweekly bisphosphonate regimen at 12 monthsFig. 1. Patient disposition and rates forpost-enrollment (82.6 vs 75.3%, p ¼ 0.005) in the overall popula-
tion, at 3-month follow-up (90.4 vs 82.8%, p ¼ 0016) and 12-month
follow-up (83.4 vs 74.2%, p ¼ 0.012) in the training group, while
similar rates for persistence were noted with respect to frequency
of treatment regimen in the control group (Table 3). KaplaneMeier
analysis also indicated higher persistence with a monthly rather
than weekly regimen (weekly: 15.9 [0.4]; monthly: 17.9 [1.2];
p ¼ 0.030, Log-rank ManteleCox) in the training group (Fig. 2c),
while no difference was found in the control group (Fig. 2d).
Training group patients were signiﬁcantly more compliant with
their treatments than controls at 3-month (47.2% vs 40%, p¼ 0.021)
and 6-month (47.3% vs 37.6%, p ¼ 0.003) follow-up visits, while no
signiﬁcance was shown at later visits. During the course of the
study, the pooled compliant and fully compliant groups constituted
an average 86.6% in the overall population, with no signiﬁcant
difference between training (87.3%) and control (86.0%) groups.
Overall, a monthly regimenwas associated with higher compliance
rates at 6-month (p ¼ 0.038), 9-month (p ¼ 0.012), and 12-month
(p ¼ 0.002) follow-up visits. Patients with monthly treatment
regimens, allocated to either the training or control groups, were
more compliant when compared to weekly regimens only at 12-
month follow-up (p ¼ 0.020 and p ¼ 0.038, respectively) (Table 4).
Among recorded withdrawals in the training (n ¼ 30) and
control (n ¼ 26) groups, the most common cause was non-
reimbursement of the cost of bisphosphonates by government
health plan on the basis of regular DXA evaluations (18/102 training
group, 10/100 control group). Patients who could not obtain their
reﬁlls were not able to continue the study. In 12 cases, study
discontinuation was related to AEs.
AEs in the training group (n ¼ 7) were mostly gastrointestinal
symptoms (nausea, n ¼ 6). One death of a 62-year-old female who
had cardiac insufﬁciency, diabetes mellitus, and hypertension was
reported, but cause of death and causality with the study drug was
not speciﬁed by the physician. In the control group, reported AEs
(n ¼ 5) were myocardial infarction (n ¼ 1), nausea due to other
medical conditions (n¼ 2), chest pain (n¼ 1), and death (n¼ 1, due
to myocardial infarction unrelated to study medication).
Discussion
Our ﬁndings revealed no difference between training and con-
trol groups in terms of treatment compliance and persistence ratesstudy completion and withdrawal.
Table 1
Socio-demographic and baseline characteristics.
Training (n ¼ 492) Control (n ¼ 487) Total (n ¼ 979)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 63.4 (7.2) 63.0 (7.1) 63.2 (7.2)
Age for menopause 46.4 (5.5) 46.0 (5.9) 46.2 (5.7)
Duration of menopause 17.0 (8.2) 17.1 (8.5) 17.0 (8.4)
Age groups (years) N (%) N (%) N (%)
45e55 81 (16.5) 84 (17.2) 165 (16.9)
56e65 202 (41.1) 208 (42.7) 410 (41.9)
66e75 209 (42.5) 195 (40.0) 404 (41.3)
Educational level N (%) N (%) N (%)
Illiterate 113 (23.0) 129 (26.5) 242 (24.7)
Primary 297 (60.4) 269 (55.2) 566 (57.8)
High school 52 (10.6) 44 (9.0) 96 (9.8)
University 30 (6.1) 45 (9.2) 75 (7.7)
Comorbid diseases 340 (69.1) 341 (70.0) 681 (69.6)
Diabetes Mellitus 63 (18.5) 71 (20.8) 134 (19.7)
Hypertension 241 (70.9) 227 (66.6) 468 (68.7)
Hyperlipidemia 118 (34.7) 121 (35.5) 239 (35.1)
Heart failure 20 (5.9) 13 (3.8) 33 (4.8)
COPD 11 (3.2) 9 (2.6) 20 (2.9)
Bronchial Asthma 26 (7.6) 29 (8.5) 55 (8.1)
Genetic Diseases 1 (0.3) 0 (0.0) 1 (0.1)
Allergy 10 (2.9) 9 (2.6) 19 (2.8)
Past history of surgical operation 260 (52.9) 273 (56.1) 533 (54.4)
Duration of comorbidity (years) N Mean (SD) N Mean (SD) N Mean (SD)
Hypertension 162 8.0 (6.3) 160 8.0 (7.0) 322 8.0 (6.6)
Hyperlipidemia 52 5.6 (4.9) 58 5.4 (4.9) 110 5.4 (4.9)
Diabetes mellitus 41 7.8 (8.0) 43 7.5 (5.3) 84 7.6 (6.7)
Vital signs N Mean (SD) N Mean (SD) N Mean (SD)
SBP (mmHg) 459 128.0 (17.0) 442 127 (17) 127.9 (16.7)
DBP(mmHg) 459 80.0 (10.0) 442 80 (10) 79.8 (10.2)
Pulse (bpm) 450 77.0 (7.0) 438 77 (7) 76.9 (7.3)
Height (cm) 469 156.0 (6.0) 471 156 (6) 156.0 (6.3)
Weight (kg) 469 68.0 (11.4) 471 67.9 (12.0) 67.9 (11.7)
Life style characteristics N (%) N (%) N (%)
Coffee consumption (>3 cups/day) 16 (3.3) 9 (1.8) 25 (2.6)
Cola consumption 7 (1.4) 6 (1.2) 13 (1.3)
(>3 glasses/day) Tea consumption (>3 glasses/day) 257 (52.2) 251 (51.5) 508 (51.9)
Alcohol consumption 16 (3.3) 19 (3.9) 35 (3.6)
Smoking 68 (13.8) 53 (10.9) 121 (12.4)
<1 package/day 37 (54.4) 37 (69.8) 74 (61.2)
1 package/day 29 (42.6) 15 (28.3) 44 (36.4)
2 packages/day 2 (2.9) 1 (1.9) 3 (2.5)
Regular consumption of milk 119 (24.2) 118 (24.2) 237 (24.2)
Regular consumption of milk products 328 (66.7) 301 (61.8) 629 (64.2)
Regular exercise 121 (24.6) 117 (24.0) 238 (24.3)
Concomitant treatments 313 (63.6) 301 (61.8) 614 (62.7)
Antihypertensive drugs 218 (69.7) 197 (65.5) 415 (67.6)
NSAIDs 30 (9.6) 33 (11.0) 63 (10.3)
Lipid lowering drugs 77 (24.6) 79 (26.3) 156 (25.4)
Antidepressant drugs 31 (9.9) 29 (9.6) 60 (9.8)
Other 104 (33.2) 93 (30.9) 197 (32.1)
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follow-up period. A monthly bisphosphonate regimen was associ-
ated with signiﬁcantly longer persistence, higher percentage of
persistent patients, and higher compliance when compared to a
weekly regimen in the overall population. A signiﬁcantly higher
percentage of persistent patients in the training group was
observed only with those on the monthly regimen. Both monthly
and weekly treatment regimens were well tolerated, with
completion of study by 74.2% of training and 76.5% of control pa-
tients on the weekly regimen, and 83.4% of training and 81.0% of
control patients on the monthly regimen.Although bisphosphonates are the preferred therapy for pre-
venting and treating osteoporosis,8 their effectiveness is severely
compromised by poor adherence,3,9 with reported failure to
comply with treatment or discontinuation of treatment in 50%e
75% of patients within 12 months of commencement.1,4
In a prior review of 14 databases in the USA, Canada, France, and
the UK, compliance with bisphosphonates was reported to range
from 59% to 81%, with persistence rates of 18%e78% at 1-year
follow-up.10 A large American prescription database study re-
ported 1-year rate of persistence with bisphosphonates to range
from 30% to 51%.11
Table 2
Osteoporosis-related baseline characteristics and study treatment.
Training (n ¼ 492) Control (n ¼ 487) Total (n ¼ 979)
N (%) N (%) N (%)
Past history of osteoporosis related fracture 99 (20.1) 103 (21.1) 202 (20.6)
Mean (SD) Mean (SD) Mean (SD)
Fracture number 1.3 (0.9) 1.4 (0.8) 1.4 (0.8)
Time since fracture (years) 5.8 (6.5) 4.5 (5.2) 5.1 (5.9)
n (%) n (%) n (%)
Compression fracture by radiography 74 (15.0) 79 (16.2) 153 (15.6)
D1-D6 7 (9.5) 14 (17.7) 21 (13.8)
D7 13 (17.6) 12 (15.2) 25 (16.3)
D8 11 (14.9) 10 (12.7) 21 (13.7)
D9 10 (13.5) 13 (16.5) 23 (15.0)
D10 14 (18.9) 6 (7.6) 20 (13.1)
D11 12 (16.2) 22 (27.9) 34 (22.2)
D12 11 (14.9) 22 (27.9) 33 (21.6)
L1 12 (16.2) 16 (20.3) 28 (18.3)
L2 12 (16.2) 10 (12.7) 22 (14.4)
L3 8 (10.8) 10 (12.7) 18 (11.8)
L4 6 (8.1) 12 (15.2) 18 (11.8)
L5 7 (9.5) 12 (15.2) 19 (12.4)
Increase in dorsal kyphosis 64 (16.1) 62 (15.5) 126 (15.8)
Bone density scan (DEXA) 469 (95.3) 471 (96.7) 940 (96.0)
Hologic 230 (49.0) 200 (42.5) 430 (45.7)
Lunar 162 (34.5) 181 (38.4) 343 (36.5)
Other 77 (16.4) 90 (19.1) 167 (17.8)
Previous anti-osteoporosis treatment 341 (69.3) 331 (68.0) 672 (68.6)
Anti-osteoporotic agent (AOA) 288 (84.5) 286 (86.4) 574 (85.4)
Exercise þ Diet þ AOA 24 (7.0) 17 (5.1) 41 (6.1)
Exercise þ AOA 12 (3.5) 11 (3.3) 23 (3.4)
Diet þ AOA 13 (3.8) 9 (2.7) 22 (3.3)
Exercise þ Diet 1 (0.3) 5 (1.5) 6 (0.9)
Diet only 2 (0.6) 2 (0.6) 4 (0.6)
Exercise only 1 (0.3) 1 (0.3) 2 (0.3)
Anti-osteoporotic agents n (%) n (%) n (%)
Alendronat 162 (27.6) 155 (28.5) 317 (28.0)
Calcium þ Vitamin D 167 (28.4) 142 (26.1) 309 (27.3)
Risedronat 107 (18.2) 95 (17.5) 202 (17.8)
Calcitonin 57 (9.7) 58 (10.7) 115 (10.2)
Ibandronat 34 (5.8) 35 (6.4) 69 (6.1)
Strontium Ranelate 28 (4.8) 25 (4.6) 53 (4.7)
SERM 24 (4.1) 23 (4.3) 47 (4.2)
Others 9 (1.5) 11 (2.1) 20 (1.8)
Total 588 (100.0) 544 (100.0) 1.132 (100.0)
Duration of anti-osteoporotic treatment (years) N Mean (SD) N Mean (SD) N Mean (SD)
Alendronat 158 2.5 (2.4) 151 2.3 (2.0) 309 2.4 (0.2)
Calcium þ Vitamin D 160 2.9 (3.6) 135 2.8 (2.3) 295 2.8 (3.1)
Risedronat 107 2.1 (1.7) 93 2.0 (1.5) 200 2.0 (1.6)
Calcitonin 57 1.8 (1.2) 56 1.7 (1.6) 113 1.7 (0.4)
Ibandronat 33 1.2 (0.8) 34 1.5 (1.3) 67 1.4 (1.1)
Strontium Ranelate 27 1.6 (1.6) 24 1.4 (0.9) 51 1.5 (1.3)
SERM 17 2.1 (1.4) 20 1.5 (1.1) 37 1.8 (1.3)
Study treatment regimen N (%) N (%) N (%)
Weekly biphosphonate 221 (44.9) 217 (44.6) 438 (44.7)
Alendronate 70 mg 124 (56.1) 122 (56.2) 246 (56.2)
Risedronate 35 mg 97 (43.9) 95 (43.8) 192 (43.8)
Monthly biphosphonate 271 (55.1) 270 (55.4) 541 (55.3)
Ibandronate 150 mg 106 (39.1) 104 (38.5) 210 (38.8)
Risedronate 75 mg 116 (42.8) 101 (37.4) 217 (40.1)
Risedronate 150 mg 49 (18.1) 65 (24.1) 114 (21.1)
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79.4% overall, 79.3% in the training, and 79.5% in the control groups,
with an average of 353.0, 355.5, and 350.4 days, respectively, of
duration during 12-month follow-up. During the course of the
study, the pooled compliant and fully compliant group remained an
average 86.3% of the study population, with compliance rates of86.6% in the overall population, 87.3% in the training, and 86.0% in
the control groups at 12-month follow-up.
Data from randomized clinical trials and analyses of large da-
tabases may be associated with falsely elevated persistence rates,
and lower rates are thus expected in real-life clinical practice.12
Hence, the rate of adherence in the present study population
Table 3
Treatment persistence for training and control groups in relation to weekly or monthly regimen.
Treatment persistence Training (n ¼ 492) Control (n ¼ 487) Total (979)
Duration (days) N Mean (SD) p value N Mean (SD) p value N Mean (SD) p value1
Overall 492 355.5 (94.6) e 487 350.4 (101.1) e 979 353.0 (97.8) 0.363
Weekly regimen 221 350.0 (106.0) 0.111 217 340 (109.0) 0.172 438 345.0 (108.0) 0.035
Monthly regimen 271 360.0 (84.0) 270 359 (94.0) 541 360.0 (89.0)
Left the
study
Ongoing/Completed p value Left the
study
Ongoing/Completed p value Left the
study
Ongoing/Completed p value
3rd month n (%) n (%) n (%) n (%) n (%) n (%)
Overall 64 (13.0) 428 (87.0) e 58 (11.9) 429 (88.1) e 122 (12.5) 857 (87.5) 0.565
Weekly regimen 38 (17.2) 183 (82.8) 0.016 27 (12.4) 190 (87.6) 0.836 65 (14.8) 373 (85.2) 0.058
Monthly regimen 17 (9.6) 245 (90.4) 31 (11.4) 239 (88.5) 57 (10.6) 484 (89.4)
6th month
Overall 93 (18.9) 399 (81.1) e 90 (18.5) 397 (81.5) e 183 (18.7) 796 (81.3) 0.744
Weekly regimen 50 (22.6) 171 (77.4) 0.082 39 (18.0) 178 (82.0) 0.647 89 (20.3) 349 (79.7) 0.351
Monthly regimen 43 (15.9) 228 (84.1) 51 (18.9) 219 (81.1) 94 (17.4) 447 (82.6)
9th month
Overall 109 (22.2) 383 (77.8) e 116 (23.8) 371 (76.2) e 225 (23.0) 754 (77.0) 0.583
Weekly regimen 51 (23.1) 170 (76.9) 0.957 54 (24.9) 163 (75.1) 0.929 105 (23.9) 333 (76.1) 0.921
Monthly regimen 58 (21.4) 213 (78.6) 62 (23.0) 208 (77.0) 120 (22.2) 421 (77.8)
12th month 102 (20.7) 390 (79.3) e 100 (20.5) 387 (79.5) e 202 (20.6) 777 (79.4) 0.939
Weekly regimen 57 (25.8) 164 (74.2) 0.012 51 (23.5) 166 (76.5) 0.146 108 (24.7) 330 (75.3) 0.005
Monthly regimen 45 (16.6) 226 (83.4) 49 (18.1) 221 (81.9) 94 (17.4) 447 (82.6)
ManneWhitney U test 1 training vs. control.
Values in bold indicate statistical signiﬁcance (p < 0.05).
Fig. 2. Treatment persistence: a) in training vs control groups, b) in weekly vs monthly treatment regimen in the overall population, c) in weekly vs monthly treatment regimen in
the training group, d) in weekly vs monthly treatment regimen in the control group. Log-rank ManteleCox test of equality of survival distributions for the different levels of
frequency: Ac2 ¼ 0.001, df ¼ 1, p ¼ 0.971; Bc2 ¼ 7.267, df ¼ 1, p ¼ 0.007; Cc2 ¼ 4.695, df ¼ 1, p ¼ 0.030; Dc2 ¼ 2.697, df ¼ 1, p ¼ 0.101.
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Table 4
Compliance with treatment in training and control groups and with respect to weekly or monthly bisphosphonate regimen.
According to randomization, n (%)
Compliance with
treatment
3rd month 6th month 9th month 12th month
Training
(n ¼ 434)
Control
(n ¼ 435)
Total
(n ¼ 869)
Training
(n ¼ 402)
Control
(n ¼ 402)
Total
(n ¼ 804)
Training
(n ¼ 388)
Control
(n ¼ 375)
Total
(n ¼ 763)
Training
(n ¼ 401)
Control
(n ¼ 392)
Total
(n ¼ 793)
Non-compliant 7 (1.6) 13 (3.0) 20 (2.3) 5 (1.2) 9 (2.2) 14 (1.7) 12 (3.1) 6 (1.6) 18 (2.4) 12 (3.0) 5 (1.3) 17 (2.1)
Partially compliant 50 (11.5) 60 (13.8) 110 (12.7) 41 (10.2) 56 (13.9) 97 (12.1) 34 (8.8) 44 (11.7) 78 (10.2) 39 (9.7) 50 (12.8) 89 (11.2)
Compliant 172 (39.6) 188 (43.2) 360 (41.4) 166 (41.3) 186 (46.3) 352 (43.8) 163 (42.0) 167 (44.5) 330 (43.3) 156 (38.9) 169 (43.1) 325 (41.0)
Fully compliant 205 (47.2) 174 (40.0) 379 (43.6) 190 (47.3) 151 (37.6) 341 (42.4) 179 (46.1) 158 (42.1) 337 (44.2) 194 (48.4) 168 (42.9) 362 (45.6)
p valuea 0.021 0.003 0.283 0.162
According to bisphosphonate regimen, n (%)
Compliance with
treatment
3rd month 6th month 9th month 12th month
Weekly
(n ¼ 187)
Monthly
(n ¼ 247)
Total
(n ¼ 434)
Weekly
(n ¼ 172)
Monthly
(n ¼ 230)
Total
(n ¼ 402)
Weekly
(n ¼ 174)
Monthly
(n ¼ 214)
Total
(n ¼ 388)
Weekly
(n ¼ 170)
Monthly
(n ¼ 231)
Total
(n ¼ 401)
Training group
Non-compliant 4 (2.1) 3 (1.2) 7 (1.6) 3 (1.7) 2 (0.9) 5 (1.2) 7 (4.0) 5 (2.3) 12 (3.1) 6 (3.5) 6 (2.6) 12 (3.0)
Partially compliant 25 (13.4) 25 (10.1) 50 (11.5) 21 (12.2) 20 (8.7) 41 (10.2) 22 (12.6) 12 (5.6) 34 (8.8) 21 (12.4) 18 (7.8) 39 (9.7)
Compliant 75 (40.1) 97 (39.3) 172 (39.6) 72 (41.9) 94 (40.9) 166 (41.3) 71 (40.8) 92 (43.0) 163 (42.0) 70 (41.2) 86 (37.2) 156 (38.9)
Fully compliant 83 (44.4) 122 (49.4) 205 (47.2) 76 (44.2) 114 (49.6) 190 (47.3) 74 (42.5) 105 (49.1) 179 (46.1) 73 (42.9) 121 (52.4) 194 (48.4)
p valuea 0.196 0.178 0.053 0.038
Control group Weekly
(n ¼ 194)
Monthly
(n ¼ 241)
Total
(n ¼ 435)
Weekly
(n ¼ 178)
Monthly
(n ¼ 224)
Total
(n ¼ 402)
Weekly
(n ¼ 167)
Monthly
(n ¼ 208)
Total
(n ¼ 375)
Weekly
(n ¼ 168)
Monthly
(n ¼ 224)
Total
(n ¼ 392)
Non-compliant 7 (3.6) 6 (2.5) 13 (3.0) 4 (2.2) 5 (2.2) 9 (2.2) 3 (1.8) 3 (1.4) 6 (1.6) 3 (1.8) 2 (0.9) 5 (1.3)
Partially compliant 22 (11.3) 38 (15.8) 60 (13.8) 27 (15.2) 29 (12.9) 56 (13.9) 22 (13.2) 22 (10.6) 44 (11.7) 25 (14.9) 25 (11.2) 50 (12.8)
Compliant 93 (47.9) 95 (39.4) 188 (43.2) 88 (49.4) 98 (43.8) 186 (46.3) 79 (47.3) 88 (42.3) 167 (44.5) 79 (47.0) 90 (40.2) 169 (43.1)
Fully compliant 72 (37.1) 102 (42.3) 174 (40.0) 59 (33.1) 92 (41.1) 151 (37.6) 63 (37.7) 95 (45.7) 158 (42.1) 61 (36.3) 107 (47.8) 168 (42.9)
p valuea 0.608 0.134 0.117 0.020
Overall Weekly
(n ¼ 381)
Monthly
(n ¼ 488)
Total
(n ¼ 869)
Weekly
(n ¼ 350)
Monthly
(n ¼ 454)
Total
(n ¼ 804)
Weekly
(n ¼ 341)
Monthly
(n ¼ 442)
Total
(n ¼ 763)
Weekly
(n ¼ 338)
Monthly
(n ¼ 455)
Total
(n ¼ 793)
Non-compliant 11 (2.9) 9 (1.8) 20 (2.3) 7 (2.0) 7 (1.5) 14 (1.7) 10 (2.9) 8 (1.9) 18 (2.4) 9 (2.7) 8 (1.8) 17 (2.1)
Partially compliant 47 (12.3) 63 (12.9) 110 (12.7) 48 (13.7) 49 (10.8) 97 (12.1) 44 (12.9) 34 (8.1) 78 (10.2) 46 (13.6) 43 (9.5) 89 (11.2)
Compliant 168 (44.1) 192 (39.3) 360 (41.4) 160 (45.7) 192 (42.3) 352 (43.8) 150 (44.0) 180 (42.7) 330 (43.3) 149(44.1) 176 (38.7) 325 (41.0)
Fully compliant 155 (40.7) 224 (45.9) 379 (43.6) 135 (38.6) 206 (45.4) 341 (42.4) 137 (40.2) 200 (47.4) 337 (44.2) 134 (39.6) 228 (50.1) 362 (45.6)
p valuea 0.181 0.038 0.012 0.002
Non-compliant:0e50% drug intake, partially compliant: 50% drug intake, compliant:75% drug intake; Fully compliant:100% drug intake.
Values in bold indicate statistical signiﬁcance (p < 0.05).
a ManneWhitney U test.
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designed to reﬂect everyday clinical practicewith limited follow-up
visits, in accordance with the primary care setting.
Furthermore, given that 81% of patients in both training and
control regimens were persistent at the 6-month follow-up visit in
our study, rate of adherence with bisphosphonate regimens in our
study population were also higher than rates reported in the
PERSIST (PERsistence Study of Ibandronate verSus alendronaTe)
study (56.6%),12 which was similarly designed.
However, while data from PERSIST showed that persistence
was signiﬁcantly higher in the antiosteoporotic treatment
(monthly ibandronate) plus patient support program group
compared with the antiosteoporotic treatment only (weekly
alendronate) group,12 our ﬁndings revealed no signiﬁcant impact
of patient training on persistence and compliance rates, whereas
signiﬁcantly better persistence and compliance was found in the
monthly regimen rather than weekly regimen bisphosphonate
treatment groups.
Data from another education-related interventions also
revealed that a patient support program with use of automated
phone calls and letters to inform the patients increased the number
of patients starting on osteoporosis medication, whereas adherence
was not signiﬁcantly different from the control group after 10
months of follow-up.13,14 Similarly, distributing an educational
leaﬂet about osteoporosis during initiation of treatment was re-
ported not to improve adherence to therapy when compared with
routine practice.15 Consistent with the concept that reducing the
complexity and frequency of dosing regimens improves adherence
and persistence with bisphosphonates in patients withosteoporosis,16,17 our ﬁndings revealed that monthly bisphospho-
nate regimen was associated with signiﬁcantly longer persistence,
higher percentage of persistent patients, and higher compliance
than weekly regimen in the overall population, along with signiﬁ-
cantly higher percentage of persistent patients in the training
group.
Indeed, better adherence in our patients treated with a monthly
rather than weekly regimen may also be associated with patient
preferences for the more convenient dosing regimen and thereby
the likelihood of physicians to focusmore onmonthly dosing and to
provide appropriate counseling for this treatment modality.7
Improvement in compliance and attaining persistence for 6
months of bisphosphonate therapy were reported to be associated
with signiﬁcant reduction in fracture risk by 51% and 28%, respec-
tively.9 Given that improving adherence may have a greater impact
than improved drug efﬁcacy on patient health outcomes,18
switching from a weekly to monthly bisphosphonate regimen
seems to offer a useful strategy for improving adherence and thus
long-term fracture prevention in Turkish patients receiving long-
term bisphosphonate therapy who are having difﬁculty
complying with daily or weekly dosage regimens.
It has been suggested that highly adherent patients engage in
more health-oriented behaviors such as following lifestyle recom-
mendations for avoiding fracture, including exercise, correction of
eyesight, and organization of the home environment to minimize
the risk of falls, which contribute to a reduction in fracture risk.9
Therefore, although no signiﬁcant impact of training on compli-
ance and persistence was observed with bisphosphonate regimens
in our study population within the 12-month follow-up period, it
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high adherence rates, along with higher awareness, of trained pa-
tients on critical points related to osteoporosis. Training seems to
be associated with longer-term beneﬁts that extend beyond 12
months.
In the present study population, only 5.4% of the patients
withdrew from the study due to AEs. Both regimens were well
tolerated, with gastrointestinal disorders being themost commonly
reported AEs, consistent with previous reports in the liter-
ature.6,11,12,19e21 The foremost limitation of the present study is the
observational design, which depended on voluntary patient infor-
mation rather than use of strict monitoring devices to determine
compliance. Nevertheless, despite the limitation of the observa-
tional design, our ﬁndings provide data in a large representative
sample of Turkish individuals with osteoporosis. Collection of data
based on follow-up visits every 3 months may be another limita-
tion, given that it may have caused better adherence to treatment
during the study period, causing the results to be confounded by
the subjects' awareness of being monitored. Our study population
consisted of both treatment-naïve patients and patients who were
currently receiving the drug regimen. Although this may be asso-
ciated with the likelihood of former training and compliance levels
with previous prescriptions to impact study ﬁndings, inclusion
criteria for the study populationwere decided to reﬂect the patient
proﬁle encountered in actual clinical practice, in which treatment-
naïve patients are infrequent in the overall osteoporosis patient
population. Furthermore, treatment-naïve and treated patients
were equally allocated to study groups during randomization. Lack
of adequate previous patient training is also a problem prevalent
among patients who are currently receiving anti-osteoporosis
treatment. Another limitation is the inability to determine treat-
ment burden despite the fact that poor adherence has a signiﬁcant
impact on health economic assessment in osteoporosis.
In conclusion, the present study concerning the impact of pa-
tient training on persistence and compliance with bisphosphonate
treatment on a weekly vs monthly basis in postmenopausal oste-
oporosis in Turkey revealed high rates of persistence and compli-
ance regardless of the use of training. However, adherence was
signiﬁcantly improved with a monthly vs weekly bisphosphonate
regimen.
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